Add to ORKGof limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine o
Background: Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with ab...
Objective: An antiretroviral regimen based on lamivudine +stavudine+protease inhibitor impairs perip...
In the late 1990s, reports of unusual changes in body fat distribution named \u2018lipodystrophy\u20...
Background: Antiretroviral treatment (cART) in HIV causes lipoatrophy. We examined predictors of ant...
Antiretroviral treatment (cART) in HIV causes lipoatrophy. We examined predictors of anthropometric ...
Antiretroviral treatment (cART) in HIV causes lipoatrophy. We examined predictors of anthropometric ...
Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV in...
Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but...
Lipoatrophy and/or central fat gain are observed frequently in patients on antiretroviral therapy (A...
BACKGROUND: Lipoatrophy and/or central fat gain are observed frequently in patients on antiretrovira...
We prospectively assessed the 1-month prevalence of abnormal body fat distribution in HIV-infected i...
Changes in body fat distribution in virologically suppressed HIV-infected patients switching from lo...
<div><h3>Background</h3><p>Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss c...
Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with abacavir/lamiv...
Objective: HIV-1 protease inhibitors (versus no protease inhibitors) and stavudine (versus zidovudin...
Background: Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with ab...
Objective: An antiretroviral regimen based on lamivudine +stavudine+protease inhibitor impairs perip...
In the late 1990s, reports of unusual changes in body fat distribution named \u2018lipodystrophy\u20...
Background: Antiretroviral treatment (cART) in HIV causes lipoatrophy. We examined predictors of ant...
Antiretroviral treatment (cART) in HIV causes lipoatrophy. We examined predictors of anthropometric ...
Antiretroviral treatment (cART) in HIV causes lipoatrophy. We examined predictors of anthropometric ...
Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV in...
Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but...
Lipoatrophy and/or central fat gain are observed frequently in patients on antiretroviral therapy (A...
BACKGROUND: Lipoatrophy and/or central fat gain are observed frequently in patients on antiretrovira...
We prospectively assessed the 1-month prevalence of abnormal body fat distribution in HIV-infected i...
Changes in body fat distribution in virologically suppressed HIV-infected patients switching from lo...
<div><h3>Background</h3><p>Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss c...
Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with abacavir/lamiv...
Objective: HIV-1 protease inhibitors (versus no protease inhibitors) and stavudine (versus zidovudin...
Background: Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with ab...
Objective: An antiretroviral regimen based on lamivudine +stavudine+protease inhibitor impairs perip...
In the late 1990s, reports of unusual changes in body fat distribution named \u2018lipodystrophy\u20...